Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for glucocorticoid-induced hyperglycemia
ChiCTR2000041308Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Sep 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in corticosteroid-induced hyperglycemia (GIH) and type 2 diabetes mellitus (T2DM), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoints: C-peptide, Pancreatic glucagon and 3 more. Started Sep 2020; status: recruiting.
02
Drugs
03
Conditions
corticosteroid-induced hyperglycemia (GIH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000041308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041308.